1. Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition?
- Author
-
Collier ME, Zhang S, Scrutton NS, and Giorgini F
- Subjects
- Animals, Humans, Kynurenine 3-Monooxygenase antagonists & inhibitors, Neuroprotective Agents pharmacology, Signal Transduction, COVID-19 immunology, COVID-19 psychology, Cognition drug effects, Cognition physiology, Inflammation metabolism, Kynurenine metabolism, Sulfonamides pharmacology, Thiazoles pharmacology, Tryptophan metabolism
- Abstract
The novel respiratory virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), emerged during late 2019 and spread rapidly across the world. It is now recognised that the nervous system can be affected in COVID-19, with several studies reporting long-term cognitive problems in patients. The metabolic pathway of tryptophan degradation, known as the kynurenine pathway (KP), is significantly activated in patients with COVID-19. KP metabolites have roles in regulating both inflammatory/immune responses and neurological functions. In this review, we speculate on the effects of KP activation in patients with COVID-19, and how modulation of this pathway might impact inflammation and reduce neurological symptoms., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF